Table 8. Survival with imatinib mesylate... | American Society of Hematology

Table 8.

Survival with imatinib mesylate versus other therapies by cytogenetic response at 3 and 6 months

	Imatinib mesylate			Historical control
Cytogenetic response	No.^*	% 4-y survival	No.	% 4-y survival	P
At 3 mo
Major	111	96	37	76	.003
Minor	31	93	13	54	.007
None	77	72	136	43	.0006
Total	219	88	186	50	< .0001
At 6 mo
Major	112	95	34	79	.04
Minor	29	96	10	60	.009
None	58	70	96	43	.02
Total	199	88	140	54	< .0001

	Imatinib mesylate			Historical control
Cytogenetic response	No.^*	% 4-y survival	No.	% 4-y survival	P
At 3 mo
Major	111	96	37	76	.003
Minor	31	93	13	54	.007
None	77	72	136	43	.0006
Total	219	88	186	50	< .0001
At 6 mo
Major	112	95	34	79	.04
Minor	29	96	10	60	.009
None	58	70	96	43	.02
Total	199	88	140	54	< .0001

Patients with insufficient metaphases or cytogenetic studies not done were excluded from this analysis.